Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 33, 08 March 2024
Open
Access | Article
Directions for the improvement of dendritic vaccines for HER2-positive breast cancer
* Author to whom correspondence should be addressed.
Abstract
Breast cancer is the disease with the largest number of diagnoses at present, which seriously threatens the health of women all over the world. HER2 positive breast cancer is one of the subtypes, accounting for 25% -30% of breast cancer cases. Despite good progress in chemotherapy, radiation therapy, endocrine therapy and other areas, cancer recovery remains a huge challenge. The development of tumor therapeutic vaccines is a promising strategy. In recent years, more and more vaccines based on different carrier platforms have gradually been discovered. These vaccines stimulate the immune system of patients to produce specific immune responses, thereby reducing the recurrence and metastasis rate of cancer. However, in current clinical research evaluations, no type of vaccine has demonstrated significant therapeutic effects. This paper summarizes the mechanism and types of DC vaccine for HER2 positive breast cancer, analyzes its shortcomings according to relevant clinical trials, and proposes solutions in some aspects such as action target, delivery vector, combined immunity, etc, provides a reference for the development and improvement of therapeutic vaccine for breast cancer in the future. At present, many studies are addressing the problems with some vaccines, and there will be better therapeutic vaccines for breast tumors applied in clinical practice in the future, benefiting all humanity.
Keywords
Breast cancer, vaccines, dendritic cells, HER2
References
1. Mengqian L Kejing Z Fan X 2023 Research progress of breast cancer vaccine Clini Pharmacol Therape in China 28 08 918-925
2. Swain SM Shastry M Hamilton E 2023 Targeting HER2-positive breast cancer advances and future directions Nat Rev Drug Discov Feb 22 2 101-126
3. Vermaelen K 2019 Vaccine Strategies to improve anti-can- cer cellular immune response Front Immunol 10 8
4. Palucka K Banchereau J 2012 Cancer immunotherapy via dendritic cells Nat Rev Cancer 12 4 265e77
5. Jianyong Liu Chunyan Zhang Yinnong Zhao et al 2003 Study of Anti-Breast Cancer Activity of Tumor Infiltrating Lymphocytes Affected by Dendritic Cells Chin J Cancer 10 1030-1033
6. FrankG MartinRM PeterB 2005 New developments in dendritic cell-based vaccinations RNA translated into clinics Cancer Immunol Immunother 54 6 517-525
7. Morse MA ClayTM ColingK et al 2003 HER2 dendritic cell vaccines Clin Breast Cancer 3 Suppl 4 164- 172
8. Chao Y Yunjiang L 2007 Research progress of dendritic cell vaccine for breast cancer treatment J cellular molec immunol 10 989-991
9. Gelao L Criscitiello C Esposito A et al 2014 Dendritic cell-based vaccines clinical applications in breast cancer Immunotherapy 6 3 349e60
10. Fujun S 2022 Research progresses of breast cancer vaccines for breast cancer J Practical Medicine 38 20 2505-2509
11. Gong J Avigan D Chen D et al 2000 Activation of anti-tumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells Proc Natl Acad Sci USA 97 6 2715-
12. Gong J Koido S 2008 Calderwood SK Cell fusion From hybridoma to dendritic cell-based vaccine Expert Rev Vaccines 7 1055–1068
13. Sadeghi S Tehrani FR 2023 Tahmasebi S Shafiee A Hashemi SM Exosome engineering in cell therapy and drug delivery Inflammopharmacology 2023 Feb 31 1 145-169
14. Thakur A Parra DC Motallebnejad P Brocchi M Chen HJ 2021 Exosomes Small vesicles with big roles in cancer vaccine development and therapeutics Bioact Mater Aug 28 10 281-294
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 2nd International Conference on Modern Medicine and Global Health
- ISBN (Print)
- 978-1-83558-323-4
- ISBN (Online)
- 978-1-83558-324-1
- Published Date
- 08 March 2024
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/33/20240881
- Copyright
- 08 March 2024
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited